

1 **Small molecule analysis of extracellular vesicles produced by *Cryptococcus gattii*:**
2 **identification of a tripeptide controlling cryptococcal infection in an invertebrate**
3 **host model**

4

5 Flavia C. G. Reis^{1,2}, Jonas H. Costa³, Leandro Honorato⁴, Leonardo Nimrichter⁴, Taícia P.
6 Fill^{3*}, and Marcio L. Rodrigues^{1,4*}

7

8 ¹*Instituto Carlos Chagas, Fundação Oswaldo Cruz (Fiocruz), Curitiba – PR, Brazil;*

9 ²*Centro de Desenvolvimento Tecnológico em Saúde (CDTS), Fiocruz, Rio de Janeiro,*
10 *Brazil;*

11 ³*Institute of Chemistry, University of Campinas, CP 6154, 13083-970, Campinas – SP,*
12 *Brazil;*

13 ⁴*Instituto de Microbiologia Paulo de Góes (IMPG), Universidade Federal do Rio de*
14 *Janeiro, Rio de Janeiro - RJ, Brazil.*

15

16 *TPF and MLR share senior authorship on this manuscript. Correspondence:

17 taicia@unicamp.br (TPF) or marcio.rodrigues@fiocruz.br (MLR).

18

19

20

21

22

23 **Abstract**

24 The small molecule (molecular mass < 900 Daltons) composition of extracellular
25 vesicles (EVs) produced by the pathogenic fungus *Cryptococcus gattii* is unknown,
26 which limits the understanding of the functions of cryptococcal EVs. In this study, we
27 analyzed the composition of small molecules in samples obtained from solid cultures
28 of *C. gattii* by a combination of chromatographic and spectrometric approaches, and
29 untargeted metabolomics. This analysis revealed previously unknown components of
30 EVs, including small peptides with known biological functions in other models. The
31 peptides found in *C. gattii* EVs had their chemical structure validated by chemical
32 approaches and comparison with authentic standards, and their functions tested in a
33 *Galleria mellonella* model of cryptococcal infection. One of the vesicular peptides
34 (isoleucine-proline-isoleucine, Ile-Pro-Ile) improved the survival of *G. mellonella*
35 lethally infected with *C. gattii* or *C. neoformans*. These results indicate that small
36 molecules exported in EVs are biologically active in *Cryptococcus*. Our study is the first
37 to characterize a fungal EV molecule inducing protection, pointing to an immunological
38 potential of extracellular peptides produced by *C. gattii*.

39

40 Introduction

41

42 *Cryptococcus gattii* is a fungal pathogen that causes disease in
43 immunocompetent individuals. This fungus was responsible for outbreaks in the Pacific
44 Northwest and in the Vancouver Island (1). *C. gattii* virulent strains, which are endemic
45 in Brazil (2), likely emerged from South America (3). *C. gattii* can cause severe lung
46 disease and death without dissemination. In contrast, its sibling species *C. neoformans*
47 disseminates readily to the central nervous system (CNS) and causes death from
48 meningoencephalitis (1). *C. gattii* and *C. neoformans* share major virulence
49 determinants, including the ability to produce extracellular vesicles (EVs) (4–6). EVs are
50 membranous structures produced by prokaryotes and eukaryotes, including fourteen
51 fungal genera (7). In fungi, they were first characterized in culture fluids of *C.*
52 *neoformans* (6). A decade later, *C. gattii* was also demonstrated to produce EVs in
53 liquid matrices (4).

54 The perception that EVs are essential players in both physiology and
55 pathogenesis of fungi is now consolidated. Much of the knowledge on the functions of
56 fungal EVs has derived from studies of their composition. During the last decade,
57 proteins, lipids, glycans, and nucleic acids were characterized as components of fungal
58 EVs (8,9). Molecules of low molecular mass, however, have been overlooked. A recent
59 study has characterized the small molecule composition of *Histoplasma capsulatum*
60 (10) and *Penicillium digitatum* EVs (11), but the low molecular mass components of
61 other fungal EVs are unknown. Considering the molecular diversity found in both *H.*
62 *capsulatum* and *P. digitatum*, it is plausible to predict that many still unknown
63 functions of EV components of low molecular mass remain to be characterized. In fact,

64 the metabolome analysis of *P. digitatum* EVs revealed the presence of
65 phytopathogenic molecules that inhibited the germination of the plant host's seeds
66 (11).

67 We have recently described a protocol for the isolation of cryptococcal EVs
68 through which the vesicles were obtained from solid fungal cultures (5). Although the
69 general properties of fungal EVs obtained from solid cultures resembled those
70 described for vesicles obtained from liquid media, a recent analysis of the protein
71 composition of cryptococcal EVs obtained from solid medium revealed important
72 differences in comparison to those obtained in early studies using liquid cultures
73 (12,13). This observation and the fact that culture conditions impact the composition
74 of small molecules in *H. capsulatum* EVs (10) reinforce the importance of the
75 compositional characterization of vesicles obtained from solid medium.

76 In this manuscript, we characterized the low mass components of EVs produced
77 by *C. gattii*. The synthesis of some of the small molecules detected in the EVs revealed
78 a vesicular peptide that protected an invertebrate host against a lethal challenge with
79 *C. gattii* in a dose-dependent fashion. These results indicate the existence of new
80 venues of exploration of the functions of EVs in fungal pathogens, and suggest that
81 small molecules of fungal EVs have immunological potential.

82

83

84

85 **Results**

86

87 **Small molecule characterization of *C. gattii* EVs.** *C. gattii* EV samples were prepared as
88 independent triplicates. EV extracts were analyzed by ultra-high performance liquid
89 chromatography-tandem mass spectrometry (UHPLC-MS/MS), and the data submitted
90 to molecular networking analysis in the Global Natural Product Social Molecular
91 Networking (GNPS) platform, an interactive online small molecule-focused tandem
92 mass spectrometry data curation and analysis infrastructure (14). Molecular
93 networking using high-resolution MS/MS spectra allows the organization of vesicular
94 compounds in a visual representation (15,16). In this analysis, each node is labeled by
95 a precursor mass and represents a MS/MS spectrum of a compound, and compounds
96 of the same molecular family are grouped together, connected by arrows, forming
97 clusters of similarity (15–18). Since the molecules can be identified in a database
98 through their fragmentation patterns and are represented in the molecular
99 networking, the benefits of this approach include fast dereplication, identification of
100 similar compounds, and effortless comparisons between different metabolic profiles
101 or conditions (16,17).

102 The cluster-based molecular networking analysis revealed secondary
103 metabolites present in the *C. gattii* EVs. The molecules detected in our analysis were
104 classified as EV components if they were detected in the three replicates. Using this
105 criterion, our small molecule analysis identified 13 genuine components of the *C. gattii*
106 EV samples (Table 1). This analysis revealed previously unknown components of EVs,
107 including peptides, amino-acids, vitamins, and a carboxylic ester. The metabolites were
108 identified through hits in the GNPS database (Supplemental Figures 1-13) and

109 corresponded to Ile-Pro-Ile (m/z 342.2384), Phe-Pro (m/z 263.1387), Pyro Glu-Ile (m/z
110 243.1335), Pyro Glu-Pro (m/z 227.1022), Leu-Pro (m/z 229.1544), Pyro Glu-Phe (m/z
111 277.1180), Val-Leu-Pro-Val-Pro (m/z 652.4025), cyclo (Trp-Pro) (m/z 284.1393), cyclo
112 (Tyr-Pro) (m/z 261.1234), tryptophan (m/z 205.0972), asperphenamate (m/z
113 507.2278), riboflavin (m/z 377.1456) and pantothenic acid (m/z 220.1181). The
114 structures and MS data of the detected metabolites are shown in Figure 1 and Table 1,
115 respectively. The cluster-based molecular networking analysis of the *C. gattii* EV
116 components is detailed in Figure 2.

117 For validation of some key GNPS hits, we performed another round of
118 spectrometric characterization of *C. gattii* small molecules including additional criteria
119 as follows. We classified as authentic EV compounds those whose structure was
120 observed in EV extracts, but not in mock samples (extracted from sterile culture
121 medium). Finally, these compounds obligatorily had chromatographic and
122 spectrometric properties similar to those of synthetic standards. Due to the easiness in
123 chemical synthesis and lack of functional information in the literature, the linear
124 dipeptides Phe-Pro, pyro-Glu-Ile, pyro-Glu-Pro, Leu-Pro, and pyro-Glu-Phe, and the
125 tripeptide Ile-Pro-Ile were selected for the validation assays. We then searched for
126 their presence in EV and mock extracts. Six peptides were classified as authentic EV
127 components according to these criteria (Table 2). Indeed, this analysis revealed similar
128 fragmentation patterns and retention times for the vesicle peptides and the standard
129 metabolites (Figure 3). The peptides exhibited typical fragments of protonated amino
130 acids at m/z 70.06, 86.09, 116.07 and 120.08 (Figure 4). In compounds containing
131 proline, fragments at m/z 116.07 and 70.06 corresponded, respectively, to the loss of
132 protonated proline and subsequent loss of H₂O and CO. In peptides composed by

133 isoleucine or leucine, fragments at m/z 132.02 and 86.09 corresponded, respectively,
134 to protonated leucine/isoleucine and subsequent loss of H₂O and CO. Finally, the loss
135 of H₂O and CO in protonated phenylalanine formed the major fragment ion at m/z
136 120.08 (19). Assuming that the vesicular components are synthesized within the cells
137 and exported extracellularly, we also analyzed cellular and supernatant extracts. The
138 six peptides listed in Table 3 were also found in these extracts (data not shown).

139

140 **Biological activity of EV peptides of *C. gattii*.** After characterization of

141 Ile-Pro-Ile, Phe-Pro, Pyro-Ile, Pyro-Pro, Leu-Pro, and Pyro-Phe as authentic EV
142 components of *C. gattii*, we used their synthetic forms to analyze their possible
143 biological activities. On the basis of the previously reported ability of fungal peptides
144 to kill bacteria (20), we initially tested their antibacterial capacity against
145 *Staphylococcus aureus* and *Pseudomonas aeruginosa*. None of the peptides had any
146 effect on microbial growth (data not shown). Since cryptococcal EVs regulate
147 intercellular communication (4), we also speculated that the peptides could mediate
148 quorum sensing, Titan cell formation or capsule growth. Once again, none of the
149 peptides had any apparent effects on these processes in *C. gattii* (data not shown).

150 It has been recently reported that fungal EVs, including cryptococcal vesicles,
151 protect mice and the invertebrate host *Galleria mellonella* against lethal challenges
152 with pathogenic fungi (12,21–23). The vesicular molecules responsible for the
153 protection remained unknown. We then asked whether the peptides listed in Table 3
154 could protect *G. mellonella* against a lethal challenge with *C. gattii*. We compared the
155 mortality curves of *G. mellonella* infected with *C. gattii* alone with the mortality of the
156 invertebrate host receiving *C. gattii* and each of the peptides at 10 µg/ml (Figure 5A).

157 Phe-Pro, Pyro-Iso, Pyr-Pro, Leu-Pro and Pyro-Phe did not have any effect on the
158 survival curves. In contrast, the tripeptide Ile-Pro-Ile significantly improved the survival
159 of *G. mellonella*. We repeated this experiment using *C. neoformans* instead of *C. gattii*
160 and obtained similar results (Figure 5B). On the basis of these results, we selected Ile-
161 Pro-Ile for tests at lower concentrations (1, 0.5 and 0.1 $\mu\text{g}/\text{ml}$) in the *C. gattii* infection
162 model. Once again, the peptide was highly efficient in prolonging the survival of
163 lethally infected *G. mellonella* in a dose-dependent fashion (Figure 6).

164

165

166

167

168 **Discussion**

169 The knowledge of the functions of fungal EVs has continuously increased in the
170 recent years (7), but the biological roles of low mass structures exported in EVs are
171 unknown. Small molecules secreted by *Cryptococcus* are immunologically active and
172 affect IL-1 β inflammasome-dependent secretion (24), but their association with EVs
173 has not been established. In our study, we aimed at proving the concept that
174 biologically active small molecules are exported in cryptococcal EVs. This idea
175 culminated with the characterization for the first time of a fungal EV molecule inducing
176 protection against pathogenic fungi.

177 Fungal EVs were demonstrated to mediate intercellular communication (4),
178 prion transmission (25), biofilm formation associated with antifungal resistance (26),
179 immunological responses *in vitro* (23,27–30), and protection of different hosts against
180 lethal challenges with fungal pathogens (12,21–23). In any of these examples, these
181 biological effects attributed to the EVs were correlated with the identification of the
182 bioactive vesicular molecules. The only known exception was the protection of *G.*
183 *mellonella* induced by cryptococcal EVs enriched with sterol glycosides and capsular
184 polysaccharides (22). However, it is important to mention that the EVs in this study
185 were produced by genetically engineered cells and, therefore, did not correspond to
186 native vesicles. It remained also unknown if other molecules influenced the protective
187 effects, since compositional studies have not been performed.

188 The identification of bioactive EV molecules is challenging in multiple aspects.
189 The compositional analysis of fungal EVs in different models include a formidable
190 variability in culture conditions, since each of the fungal pathogens tested so far
191 manifest growth particularities. In this scenario, biomarkers of fungal EVs are still not

192 known, although it has been suggested that mannoproteins and claudin-like Sur7
193 family proteins are important components of vesicles produced by *C. neoformans* and
194 *C. albicans*, respectively (12,31). The knowledge of small molecules mediating
195 important biological activities in fungal EVs is even more limited. In *H. capsulatum*,
196 carbohydrate metabolites were abundantly detected in EVs, in addition to L-ornithine
197 and ethanolamine, among other small molecules (10). In the plant pathogen *P.*
198 *digitatum*, EVs were characterized as the carriers of tryptoquialanine A, a toxin that
199 inhibited the germination of orange seeds (11). So far, tryptoquialanine A is the only
200 low mass component of fungal EVs with a reported function. In this model, the
201 mycotoxin fungisporin was also detected (11), but its function in fungal EVs remains to
202 be determined. Together, these findings illustrate the need for an improved
203 knowledge of the composition and functions of EV metabolites in fungi.

204 The isolation of cryptococcal EVs from solid medium is much more efficient
205 than the similar protocols using liquid cultures (5). RNA and proteins in cryptococcal
206 EVs obtained in liquid cultures were characterized in early studies (8,32), but their
207 distribution in EVs obtained from solid medium was only recently described in *C.*
208 *neoformans* (12). Other molecules remained unknown, and the metabolite
209 composition of cryptococcal EVs has not been investigated so far. In our study, we
210 initially aimed at understanding what are the low molecular weight components
211 exported by *C. gattii* in solid medium. We identified small molecules of different
212 chemical natures as putative components of cryptococcal EVs, but their functions
213 remain widely unknown. However, our chemical and biological methods for structural
214 validation revealed that one tripeptide was capable to protect *G. mellonella* against
215 lethal challenges with *C. gattii* or *C. neoformans*. The mechanisms by which the

216 peptides induced protection against cryptococcal infection remain unknown, but the
217 immune response of *G. mellonella* is innate and relies on the activity of hemocytes in
218 combination with antimicrobial peptides and lytic enzymes, among others (33).
219 Accordingly, immunity to *Cryptococcus* relies on innate immune cells coordinating
220 adaptive responses to stimulate fungal killing (34). Therefore, we hypothesize that the
221 tripeptide identified in our study is an inducer of innate responses, which have a key
222 general role in the control of fungal infections (35).

223 The peptide inducing protection against *Cryptococcus* in *G. mellonella* was
224 demonstrated to have important biological activities in other models. Ile-Pro-Ile, also
225 known as diprotin A, is an inhibitor of dipeptidyl peptidase 4, an enzyme participating
226 in insulin metabolism (36) and chemotaxis of murine embryonic stem cells towards
227 stromal cell-derived factor-1 (37). Its role in fungal physiology and/or pathogenesis are
228 still unknown. Noteworthy, our study did not elucidate any physiological or pathogenic
229 functions. Instead, we present a proof of concept that fungal EVs are the vehicles for
230 exporting biologically active molecules of low molecular mass that may be involved in
231 immunological and/or pathogenic mechanisms. Since fungal EVs have been
232 consistently proposed as vaccine candidates in different models, the potential of these
233 findings can be substantial.

234

235

236

237 **Methods**

238

239 **Preparation of EVs.** The EV-producing isolate used in this study was the standard strain

240 R265 of *C. gattii*. Of note, the R265 strain has been recently reclassified as *C.*

241 *deuterogattii* (38). In this study, we kept its classification as *C. gattii*, as largely

242 employed in the *Cryptococcus* literature. EV isolation was based on the protocol that

243 we have recently established for *C. gattii* and other fungal species (5). Briefly, One

244 colony of *C. gattii* R265 cultivated in solid Sabouraud's medium was inoculated into

245 yeast extract-peptone-dextrose (YPD) medium (5 ml) and cultivated for 1 day at 30°C

246 with shaking. The cell density was adjusted to of 3.5×10^7 cells/ml in YPD. From this

247 suspension, aliquots of 300 μ l were taken for inoculation in YPD agar plates, which

248 were cultivated for 1 day at 30°C. The cells were recovered from the plates with an

249 inoculation loop and transferred to a single centrifuge tube containing 30 ml of PBS

250 filtered through 0.22- μ m-pore membranes. The cells were then removed by

251 centrifugation ($5,000 \times g$ for 15 min at 4°C), and the supernatants were centrifuged

252 again ($15,000 \times g$ for 15 min at 4°C) to remove debris. The resulting supernatants were

253 filtered through 0.45- μ m-pore syringe filters and again centrifuged ($100,000 \times g$, 1 h at

254 4°C). Supernatants were discarded and pellets suspended in 300 μ l of sterile PBS. To

255 avoid the characterization of medium components as EV molecules, mock (control)

256 samples were similarly prepared using sterile plates containing YPD. Four petri dishes

257 were used for each EV isolation, and EV isolation was performed independently three

258 times. In all samples, the properties of EVs and their concentration was monitored by

259 nanoparticle tracking analysis (NTA) as described by our group (5). The samples

260 prepared for mass spectrometry analyses had the typical properties of *C. gattii* EVs
261 (data not shown), and were in the range of 4 to 6 x 10¹⁰ EVs within the triplicate set.

262

263 **Mass spectrometry analyses.** *C. gattii* EVs were vacuum dried and extracted with 1 ml
264 of methanol during 1 h in an ultrasonic bath. The extracts were filtered (0.22 µm),
265 dried under a gentle N₂ flux and stored at -20 °C. EV extracts were resuspended in 200
266 µl of MeOH and transferred into glass vials. Ultra high-performance liquid
267 chromatography-mass spectrometry (UHPLC-MS) analyses were performed using a
268 Thermo Scientific QExactive® hybrid Quadrupole-Orbitrap mass spectrometer with the
269 following parameters: electrospray ionization in positive mode, capillary voltage at 3.5
270 kV; capillary temperature at 300 °C; S-lens of 50 V and *m/z* range of 100.00-1500.00.
271 Tandem Mass spectrometry (MS/MS) was performed using normalized collision energy
272 (NCE) of 20, 30 and 40 eV; maximum 5 precursors per cycle were selected. Stationary
273 phase was a Waters ACQUITY UPLC® BEH C18 1.7 µm (2.1 mm x 50 mm) column.
274 Mobile phases were 0.1 % (v/v) formic acid in water (A) and acetonitrile (B). Eluent
275 profile (A:B) 0-10 min, gradient from 95:5 up to 2:98; held for 5 min; 15-16.2 min
276 gradient up to 95:5; held for 3.8 min. Flow rate was 0.2 mL min⁻¹. Injection volume was
277 3 µL. UHPLC-MS operation and spectra analyses were performed using Xcalibur
278 software (version 3.0.63).

279

280 **Molecular Network.** A molecular network was created using the online workflow
281 (<https://ccms-ucsd.github.io/GNPSDocumentation/>) on the GNPS website
282 (<http://gnps.ucsd.edu>). The data was filtered by removing all MS/MS fragment ions
283 within +/- 17 Da of the precursor *m/z*. MS/MS spectra were window filtered by

284 choosing only the top 6 fragment ions in the +/- 50Da window throughout the
285 spectrum. The precursor ion mass tolerance was set to 0.02 Da and a MS/MS fragment
286 ion tolerance of 0.02 Da. A network was then created where edges were filtered to
287 have a cosine score above 0.5 and more than 5 matched peaks. Further, edges
288 between two nodes were kept in the network if and only if each of the nodes
289 appeared in each other's respective top 10 most similar nodes. Finally, the maximum
290 size of a molecular family was set to 100, and the lowest scoring edges were removed
291 from molecular families until the molecular family size was below this threshold. The
292 spectra in the network were then searched against GNPS' spectral libraries. The library
293 spectra were filtered in the same manner as the input data. All matches kept between
294 network spectra and library spectra were required to have a score above 0.5 and at
295 least 5 matched peaks (14).

296

297 **Peptides.** The peptides selected for biological tests were synthesized by GenOne
298 Biotechnologies (<https://www.genone.com.br>, Rio de Janeiro, Brazil). Purity and
299 structural properties of each peptide were confirmed by high-performance liquid
300 chromatography coupled to mass spectrometry. All peptides were water-soluble and
301 had their purity at the 95% range.

302

303 ***Galleria mellonella* infection model.** Groups of 10 larvae (250 – 350 mg) were infected
304 with 10 µl of sterile PBS containing 10⁶ cells of *C. gattii* or *C. neoformans* into the last
305 left proleg using a Hamilton micro-syringe. Control systems were injected with PBS
306 alone. Fungal inoculation was followed by injection of 10 µl PBS solutions containing
307 Ile-Pro-Ile, Phe-Pro, Pyro-Ile, Pyro-Pro, Leu-Pro, and Pyro-Phe at 10 µg/ml. Due to its

308 promising effects, Ile-Pro-Ile was also tested at 1, 0.5, and 0.1 $\mu\text{l/ml}$ in a *C. gattii* model
309 of infection. Injected larvae were placed in sterile Petri dishes and incubated at 37°C.
310 The survival was monitored daily in a period of seven days. Larvae were considered
311 dead if they did not respond to physical stimulus. Statistical analysis was performed
312 using the Graphpad Prism software, version 8.0.

313

314

315 **Figures and legends**

316

317 **Figure 1.** Structures of the metabolites identified in *C. gatti* EVs through the GNPS

318 MS/MS database.

319

320 **Figure 2.** Clusters A and B of the molecular networking obtained for the *C. gattii* EV

321 cargo. Nodes circled in blue indicate molecules identified by comparison with the

322 GNPS platform database. Authentic standards were used to validate the hits within the

323 GNPS database.

324

325 **Figure 3.** Structural analysis of EV peptides produced by *C. gattii*, including Ile-Pro-Ile

326 (A), pyr-Glu-Phe (B), Phe-Pro (C), pyr-Glu-Ile (D), Leu-Pro (E), and pyr-Glu-Pro (F). For

327 each peptide, the chromatographic separation of synthetic standards, EV extracts, and

328 control (mock) samples is presented on the left side of each panel. The peaks with

329 retention times similar to the corresponding standards (red boxed area) were selected

330 for MS analyses, which are shown on the right side of each panel. These analyses

331 confirmed that the structural match between the EV components and the synthetic

332 standards.

333

334 **Figure 4.** Main mass fragments obtained for amino acids leucine, proline and

335 phenylalanine.

336

337

338

339 **Figure 5.** Effects of the EV peptides (10 µg/ml) on the survival of *G. mellonella* lethally
340 infected with *C. gattii* R265 (Cg; A) or *C. neoformans* H99 (Cn; B). A. Ile-Pro-Ile was the
341 only peptide prolonging the survival of *G. mellonella*. The other peptides did not
342 interfere with the host's survival. The experiment illustrated in A was repeated using *C.*
343 *neoformans* H99 instead of *C. gattii* R265, producing similar results.

344

345 **Figure 6.** Dose-dependent protection of *G. mellonella* against *C. gattii* (Cg) induced by
346 Ile-Pro-Ile. Survival of *G. mellonella* after injection with PBS (control) or with *C. gattii*
347 yeast cells (left panel) is shown, in addition to the comparative survival curves of *G.*
348 *mellonella* after injection with *C. gattii* alone (red curves) or with the fungus in the
349 presence of variable concentrations of Ile-Pro-Ile.

350 **Table 1.** MS data obtained for *Cryptococcus gattii* secondary metabolites detected on
351 EVs.

| Compound | Ion formula | Calculated <i>m/z</i> | Experimental <i>m/z</i> | Error (ppm) |
|--------------------------|---|----------------------------------|------------------------------------|--------------------|
| Ile-Pro-Ile (Diprotin A) | C ₁₇ H ₃₂ N ₃ O ₄ | 342.2392 | 342.2384 | -1.1 |
| Phe-Pro | C ₁₄ H ₁₉ N ₂ O ₃ | 263.1395 | 263.1387 | -1.3 |
| Pyro Glu-Ile | C ₁₁ H ₁₉ N ₂ O ₄ | 243.1344 | 243.1335 | -1.8 |
| Pyro Glu-Pro | C ₁₀ H ₁₅ N ₂ O ₄ | 227.1031 | 227.1022 | -1.7 |
| Leu-Pro | C ₁₁ H ₂₁ N ₂ O ₃ | 229.1552 | 229.1544 | -1.4 |
| Pyro Glu-Phe | C ₁₄ H ₁₇ N ₂ O ₄ | 277.1188 | 277.1180 | -1.0 |
| Val-Leu-Pro-Val-Pro | C ₃₁ H ₅₄ N ₇ O ₈ | 652.4033 | 652.4025 | -1.2 |
| Cyclo(Trp-Pro) | C ₁₆ H ₁₈ N ₃ O ₂ | 284.1399 | 284.1393 | -2.1 |
| Cyclo(Tyr-Pro) | C ₁₄ H ₁₇ N ₂ O ₃ | 261.1239 | 261.1234 | -1.9 |
| Tryptophan | C ₁₁ H ₁₃ N ₂ O ₂ | 205.0977 | 205.0972 | -2.4 |
| Asperphenamate | C ₃₂ H ₃₁ N ₂ O ₄ | 507.2283 | 507.2278 | -1.0 |
| Riboflavin | C ₁₇ H ₂₁ N ₄ O ₆ | 377.1461 | 377.1456 | -1.3 |
| Pantothenic acid | C ₉ H ₁₈ NO ₅ | 220.1184 | 220.1181 | -1.3 |

352
353

354 **Table 2. Chromatographic identification of peptides in cryptococcal EVs*.**

355 **Sample (retention time, min)**

| Peptide | Control | Mock | EVs | Synthetic standards |
|-------------|---------|------|---------------|---------------------|
| Ile-Pro-Ile | NF | NF | 4.03 | 3.76 |
| Phe-Pro | NF | NF | 3.18 and 3.64 | 3.28 and 3.62 |
| Pyro-Ile | NF | NF | 3.55 | 3.53 |
| Pyro-Pro | NF | NF | 1.8 | 1.8 |
| Leu-Pro | NF | NF | 2.83 | 2.78 |
| Pyro-Phe | NF | NF | 4 | 4 |

356

357 *Peptide identification was performed in blank samples (control) in addition to
358 preparations obtained from sterile medium (mock) or fungal EVs. The results were
359 compared to those obtained with synthetic peptides. NF, not found.

360

361 **Acknowledgements**

362 M.L.R. is currently on leave from the position of associate professor at the
363 Microbiology Institute of the Federal University of Rio de Janeiro, Brazil. M.L.R. is
364 supported by grants from the Brazilian Ministry of Health (grant 440015/2018-9),
365 Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq; grants
366 405520/2018-2 and 301304/2017-3), and Fiocruz (grants PROEP-ICC 442186/2019-3,
367 VPPCB-007-FIO-18, and VPPIS-001-FIO18). JHC and FCGR were financed in part by
368 scholarships from the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
369 (CAPES, Brazil, Finance Code 001). MLR also acknowledges support from the Instituto
370 Nacional de Ciência e Tecnologia de Inovação em Doenças de Populações
371 Negligenciadas (INCT-IDPN). The funders had no role in the decision to publish, or
372 preparation of the manuscript.

373

374 **Conflict of interest statement:** The authors report no conflict of interest.

375

376 **References**

- 377 1. Kwon-Chung KJ, Fraser JA, Doering TÁL, Wang ZA, Janbon G, Idnurm A, Bahn YS.
378 *Cryptococcus neoformans* and *Cryptococcus gattii*, the etiologic agents of
379 cryptococcosis. *Cold Spring Harb Perspect Med* (2015)
380 doi:10.1101/cshperspect.a019760
- 381 2. Fernando Silva Rocha D, Cruz KS, da Silva Santos CS, Stephanny Fernandes
382 Menescal L, da Silva Neto JR, Pinheiro SB, Silva LM, Trilles L, Vicente Braga de
383 Souza J. MLST reveals a clonal population structure for *Cryptococcus*
384 *neoformans* molecular type VNI isolates from clinical sources in Amazonas,
385 Northern-Brazil. *PLoS One* (2018) doi:10.1371/journal.pone.0197841
- 386 3. Hagen F, Ceresini PC, Polacheck I, Ma H, van Nieuwerburgh F, Gabaldón T, Kagan
387 S, Pursall ER, Hoogveld HL, van Iersel LJJ, et al. Ancient Dispersal of the Human
388 Fungal Pathogen *Cryptococcus gattii* from the Amazon Rainforest. *PLoS One*
389 (2013) doi:10.1371/journal.pone.0071148
- 390 4. Bielska E, Sisquella MA, Aldeieg M, Birch C, O'Donoghue EJ, May RC. Pathogen-
391 derived extracellular vesicles mediate virulence in the fatal human pathogen
392 *Cryptococcus gattii*. *Nat Commun* (2018) 9: doi:10.1038/s41467-018-03991-6
- 393 5. Reis FCG, Borges BS, Jozefowicz LJ, Sena BAG, Garcia AWA, Medeiros LC, Martins
394 ST, Honorato L, Schrank A, Vainstein MH, et al. A novel protocol for the isolation
395 of fungal extracellular vesicles reveals the participation of a putative scramblase
396 in polysaccharide export and capsule construction in *Cryptococcus gattii*.
397 *mSphere* (2019) 4:e00080-19. doi:10.1128/mSphere .00080-19
- 398 6. Rodrigues ML, Nimrichter L, Oliveira DL, Frases S, Miranda K, Zaragoza O,
399 Alvarez M, Nakouzi A, Feldmesser M, Casadevall A. Vesicular polysaccharide


- 400 export in *Cryptococcus neoformans* is a eukaryotic solution to the problem of
401 fungal trans-cell wall transport. *Eukaryot Cell* (2007) **6**: doi:10.1128/EC.00318-06
- 402 7. Rizzo J, Rodrigues ML, Janbon G. Extracellular Vesicles in Fungi: Past, Present,
403 and Future Perspectives. *Front Cell Infect Microbiol* (2020) **10**:
404 doi:10.3389/fcimb.2020.00346
- 405 8. Rodrigues ML, Nakayasu ES, Almeida IC, Nimrichter L. The impact of proteomics
406 on the understanding of functions and biogenesis of fungal extracellular
407 vesicles. *J Proteomics* (2014)97:177-186. doi:10.1016/j.jprot.2013.04.001
- 408 9. de Toledo Martins S, Szwarc P, Goldenberg S, Alves LR. Extracellular Vesicles in
409 Fungi: Composition and Functions. *Curr Top Microbiol Immunol* (2019) **422**:45–
410 59. doi:10.1007/82_2018_141
- 411 10. Cleare LG, Zamith D, Heyman HM, Couvillion SP, Nimrichter L, Rodrigues ML,
412 Nakayasu ES, Nosanchuk JD. Media matters! Alterations in the loading and
413 release of *Histoplasma capsulatum* extracellular vesicles in response to different
414 nutritional milieus. *Cell Microbiol* (2020) doi:10.1111/cmi.13217
- 415 11. Costa JH, Bazioli JM, Barbosa LD, dos Santos Júnior PLT, Reis FCG, Klimeck T,
416 Crnkovic CM, Berlinck RGS, Sussulini A, Rodrigues ML, et al. Phytotoxic
417 tryptoquialanines produced &em>in vivo&/em> by
418 &em>*Penicillium digitatum*&/em> are exported in extracellular
419 vesicles. *bioRxiv* (2020)2020.12.03.411132. doi:10.1101/2020.12.03.411132
- 420 12. Rizzo juliana, Wong SSW, Gazi AD, Moyrand F, Chaze T, Commere P-H, Matondo
421 M, Novault S, PEHAU-ARNAUDET G, Reis F, et al. New insights into *Cryptococcus*
422 extracellular vesicles suggest a new structural model and an antifungal vaccine
423 strategy. *bioRxiv* (2020)2020.08.17.253716. doi:10.1101/2020.08.17.253716

- 424 13. Rodrigues ML, Nakayasu ES, Oliveira DL, Nimrichter L, Nosanchuk JD, Almeida IC,
425 Casadevall A. Extracellular vesicles produced by *Cryptococcus neoformans*
426 contain protein components associated with virulence. *Eukaryot Cell* (2008) **7**:
427 doi:10.1128/EC.00370-07
- 428 14. Wang M, Carver JJ, Phelan V V., Sanchez LM, Garg N, Peng Y, Nguyen DD,
429 Watrous J, Kapon CA, Luzzatto-Knaan T, et al. Sharing and community curation
430 of mass spectrometry data with Global Natural Products Social Molecular
431 Networking. *Nat Biotechnol* (2016) doi:10.1038/nbt.3597
- 432 15. Krug D, Müller R. Secondary metabolomics: The impact of mass spectrometry-
433 based approaches on the discovery and characterization of microbial natural
434 products. *Nat Prod Rep* (2014) doi:10.1039/c3np70127a
- 435 16. Purves K, Macintyre L, Brennan D, Hreggviðsson G, Kuttner E, Ásgeirsdóttir ME,
436 Young LC, Green DH, Edrada-Ebel R, Duncan KR. Using molecular networking for
437 microbial secondary metabolite bioprospecting. *Metabolites* (2016)
438 doi:10.3390/metabo6010002
- 439 17. Watrous J, Roach P, Alexandrov T, Heath BS, Yang JY, Kersten RD, Van Der Voort
440 M, Pogliano K, Gross H, Raaijmakers JM, et al. Mass spectral molecular
441 networking of living microbial colonies. *Proc Natl Acad Sci U S A* (2012)
442 doi:10.1073/pnas.1203689109
- 443 18. Nguyen DD, Wu CH, Moree WJ, Lamsa A, Medema MH, Zhao X, Gavilan RG,
444 Aparicio M, Atencio L, Jackson C, et al. MS/MS networking guided analysis of
445 molecule and gene cluster families. *Proc Natl Acad Sci U S A* (2013)
446 doi:10.1073/pnas.1303471110
- 447 19. Zhang P, Chan W, Ang IL, Wei R, Lam MMT, Lei KMK, Poon TCW. Revisiting


- 448 Fragmentation Reactions of Protonated α -Amino Acids by High-Resolution
449 Electrospray Ionization Tandem Mass Spectrometry with Collision-Induced
450 Dissociation. *Sci Rep* (2019) doi:10.1038/s41598-019-42777-8
- 451 20. Kombrink A, Tayyrov A, Essig A, Stöckli M, Micheller S, Hintze J, van Heuvel Y,
452 Dürig N, Lin C wei, Kallio PT, et al. Induction of antibacterial proteins and
453 peptides in the coprophilous mushroom *Coprinopsis cinerea* in response to
454 bacteria. *ISME J* (2019) doi:10.1038/s41396-018-0293-8
- 455 21. Vargas G, Honorato L, Guimarães AJ, Rodrigues ML, Reis FCG, Vale AM, Ray A,
456 Nosanchuk JD, Nimrichter L. Protective effect of fungal extracellular vesicles
457 against murine candidiasis. *Cell Microbiol* (2020) doi:10.1111/cmi.13238
- 458 22. Ana Caroline Colombo, Rella A, Normile T, Joffe LS, Tavares PM, Glauber GR,
459 Frases S, Orner EP, Farnoud AM, Fries BC, et al. *Cryptococcus neoformans*
460 glucuronoxylomannan and sterylglucoside are required for host protection in an
461 animal vaccination model. *MBio* (2019) doi:10.1128/mBio.02909-18
- 462 23. Vargas G, Rocha JDB, Oliveira DL, Albuquerque PC, Frases S, Santos SS,
463 Nosanchuk JD, Gomes AMO, Medeiros LCAS, Miranda K, et al. Compositional
464 and immunobiological analyses of extracellular vesicles released by *Candida*
465 *albicans*. *Cell Microbiol* (2015) **17**:389–407. doi:10.1111/cmi.12374
- 466 24. Bürgel PH, Marina CL, Saavedra PHV, Albuquerque P, Holanda PH, de Araújo
467 Castro R, Heyman H, Coelho C, Cordero RJB, Casadevall A, et al. *Cryptococcus*
468 *neoformans* secretes small molecules that inhibit IL-1 β inflammasome-
469 dependent secretion. *bioRxiv* (2019) doi:10.1101/554048
- 470 25. Kabani M, Melki R. Sup35p in its soluble and prion states is packaged inside
471 extracellular vesicles. *MBio* (2015) **6**: doi:10.1128/mBio.01017-15

- 472 26. Zarnowski R, Sanchez H, Covelli AS, Dominguez E, Jaromin A, Bernhardt J,
473 Mitchell KF, Heiss C, Azadi P, Mitchell A, et al. *Candida albicans* biofilm-induced
474 vesicles confer drug resistance through matrix biogenesis. *PLOS Biol* (2018)
475 doi:10.1371/journal.pbio.2006872
- 476 27. Oliveira DL, Freire-de-Lima CG, Nosanchuk JD, Casadevall A, Rodrigues ML,
477 Nimrichter L. Extracellular vesicles from *Cryptococcus neoformans* modulate
478 macrophage functions. *Infect Immun* (2010) doi:10.1128/IAI.01171-09
- 479 28. Da Silva TA, Roque-Barreira MC, Casadevall A, Almeida F. Extracellular vesicles
480 from *Paracoccidioides brasiliensis* induced M1 polarization in vitro. *Sci Rep*
481 (2016) doi:10.1038/srep35867
- 482 29. Bitencourt TA, Rezende CP, Quaresimin NR, Moreno P, Hatanaka O, Rossi A,
483 Martinez-Rossi NM, Almeida F. Extracellular vesicles from the dermatophyte
484 trichophyton interdigitale modulate macrophage and keratinocyte functions.
485 *Front Immunol* (2018) doi:10.3389/fimmu.2018.02343
- 486 30. Almeida F, Wolf JM, Da Silva TA, Deleon-Rodriguez CM, Rezende CP, Pessoni
487 AM, Fernandes FF, Silva-Rocha R, Martinez R, Rodrigues ML, et al. Galectin-3
488 impacts *Cryptococcus neoformans* infection through direct antifungal effects.
489 *Nat Commun* (2017) doi:10.1038/s41467-017-02126-7
- 490 31. Dawson CS, Garcia-Ceron D, Rajapaksha H, Faou P, Bleackley MR, Anderson MA.
491 Protein markers for *Candida albicans* EVs include claudin-like Sur7 family
492 proteins. *J Extracell Vesicles* (2020) doi:10.1080/20013078.2020.1750810
- 493 32. Da Silva RP, Puccia R, Rodrigues ML, Oliveira DL, Joffe LS, César G V., Nimrichter
494 L, Goldenberg S, Alves LR. Extracellular vesicle-mediated export of fungal RNA.
495 *Sci Rep* (2015) 5:7763. doi:10.1038/srep07763


- 496 33. Trevijano-Contador N, Zaragoza O. Immune response of *Galleria mellonella*
497 against human fungal pathogens. *J Fungi* (2019) doi:10.3390/jof5010003
- 498 34. Gibson JF, Johnston SA. Immunity to *Cryptococcus neoformans* and *C. gattii*
499 during cryptococcosis. *Fungal Genet Biol* (2015) doi:10.1016/j.fgb.2014.11.006
- 500 35. Shoham S, Levitz SM. The immune response to fungal infections. *Br J Haematol*
501 (2005) doi:10.1111/j.1365-2141.2005.05397.x
- 502 36. Kieffer TJ, Mc Intosh CHS, Pederson RA. Degradation of glucose-dependent
503 insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in
504 vivo by dipeptidyl peptidase iv. *Endocrinology* (1995)
505 doi:10.1210/endo.136.8.7628397
- 506 37. Guo Y, Hangoc G, Bian H, Pelus LM, Broxmeyer HE. SDF-1/CXCL12 Enhances
507 Survival and Chemotaxis of Murine Embryonic Stem Cells and Production of
508 Primitive and Definitive Hematopoietic Progenitor Cells. *Stem Cells* (2005)
509 doi:10.1634/stemcells.2005-0085
- 510 38. Hagen F, Khayhan K, Theelen B, Kolecka A, Polacheck I, Sionov E, Falk R,
511 Parnmen S, Lumbsch HT, Boekhout T. Recognition of seven species in the
512 *Cryptococcus gattii/Cryptococcus neoformans* species complex. *Fungal Genet*
513 *Biol* (2015) doi:10.1016/j.fgb.2015.02.009
- 514




Ile-Pro-Ile




Phe-Pro




Pyro Glu-Ile




Pyro Glu-Pro




Leu-Pro




Pyro Glu-Phe




Val-Leu-Pro-Val-Pro




Cyclo(Trp-Pro)




Cyclo(Tyr-Pro)




Tryptophan









Asperphenamate




Pantothenic Acid





Riboflavin


A**D****B****E****C****F**





ion proline
 m/z 116.07




m/z 70.06





ion leucine
 m/z 132.10



m/z 86.09




ion phenylalanine
 m/z 166.08



m/z 120.08

A



B

